Alan Leeds

Alan Leeds, a partner in the corporate practice, represents life sciences companies from early-stage biotechnology startups to global pharmaceutical companies, as well as specialty pharma, medical device, and other technology companies. Alan’s practice includes negotiating and structuring strategic alliances and other complex collaborations, corporate partnering arrangements, licensing transactions, product acquisitions and divestitures, manufacturing and supply agreements, distribution arrangements, co-promotion arrangements, and joint ventures.

Alan assists clients with the full spectrum of commercial activities, from early-stage research collaborations to global strategic alliances for the development and commercialization of products. In addition, he advises on financing transactions such as equity investments and royalty monetization with a focus on the life sciences industry.

Alan is the author or co-author of a number of articles relating to the life sciences industry, including, in the New Jersey Law Journal, “Keep One Eye on the Collaboration, And the Other on Exit Events,” and “Dividing the Intellectual Property Pie in the Life Sciences Industry.” Heis also a contributor to Morgan Lewis’s Emerging Life Sciences Companies Deskbook. He has spoken on subjects related to the life sciences industry at various life sciences–related conferences, including Licensing Executives Society (LES) annual meetings.

To learn more about Alan and his experience, please go to: https://www.morganlewis.com/bios/aleeds.

University of Pennsylvania, Wharton School of Business, B.S., 1996; Harvard Law School, J.D., 1999